Merck Buys San Diego's Cidara Therapeutics for $9.2 Billion
Merck completed its $9.2 billion acquisition of Cidara Therapeutics, gaining control of CD388, an experimental flu drug. CD388 showed 76.1% efficacy in preventing flu in healthy adults in a Phase 2b trial, but further testing is needed for high-risk groups. Merck paid $221.50 per share for Cidara, with 85.96% of shares tendered. The FDA granted CD388 Breakthrough Therapy Designation, and Phase 3 trials are ongoing.
How this was made

The 30-second read
Why it matters
The acquisition could reshape Merck's revenue mix and affect its valuation metrics.
Market read
A major M&A deal with significant cash outlay and pipeline implications, likely to move Merck's stock in the short term.
What to watch
Regulatory timeline for CD388 approval and potential competition from next‑gen antivirals.
Background
Merck's strategic move aims to expand its infectious‑disease portfolio with a novel, long‑acting antiviral.
Ticker impact
Merck completed its $9.2 billion acquisition of Cidara Therapeutics, gaining control of the CD388 flu drug candidate.
likely modest downside as the market prices the acquisition cost, with upside potential if CD388 succeeds in Phase 3.
Acquisition size and new antiviral asset are material; traders may short or hedge MRK pending Phase 3 results.
Market effects
Adds a new antiviral candidate to Merck's pipeline, potentially strengthening its infectious‑disease franchise.
May influence US biotech M&A activity as larger pharma seek similar assets.
Could affect global flu‑treatment outlook if CD388 proves effective.
Counterpoint
The high acquisition price may overvalue an unproven drug, risking dilution of Merck's earnings.
Key entities
- CompanyMerck & Co.
US‑listed pharmaceutical giant completing the acquisition.
- CompanyCidara Therapeutics
San Diego biotech developing CD388, now owned by Merck.



